Add Presentation to Slide Tray Presentation:
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Conclusions (3 of 3)
- There is little evidence from head-to-head comparisons of first-generation antipsychotics and second-generation antipsychotics to estimate differences in risk for the most clinically important adverse effects: mortality, diabetes mellitus, tardive dyskinesia, and metabolic syndrome.
- Clinical studies are still lacking to describe comparative long-term efficacy and safety, optimal dosage and duration of treatment, and risks and benefits in patient subpopulations.
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.